Rxsight Inc (RXST) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.41 is considered Undervalued compared with the five-year average of -27.24. The fair price of Rxsight Inc (RXST) is between 8.97 to 21.78 according to relative valuation method. Compared to the current price of 7.61 USD , Rxsight Inc By Undervalued By 15.18%.

Relative Value

Fair Zone

8.97-21.78

Current Price：7.61

15.18%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Rxsight Inc (RXST) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Rxsight Inc (RXST) has a current Price-to-Book (P/B) ratio of 1.55. Compared to its 3-year average P/B ratio of 5.95, the current P/B ratio is approximately -74.03% higher. Relative to its 5-year average P/B ratio of 4.77, the current P/B ratio is about -67.62% higher. Rxsight Inc (RXST) has a Forward Free Cash Flow (FCF) yield of approximately -5.20%. Compared to its 3-year average FCF yield of -4.26%, the current FCF yield is approximately 22.13% lower. Relative to its 5-year average FCF yield of -7.98%, the current FCF yield is about -34.80% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RXST competitors is 1.84, providing a benchmark for relative valuation. Rxsight Inc Corp (RXST.O) exhibits a P/S ratio of 3.41, which is 85.74% above the industry average. Given its robust revenue growth of -18.91%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RXST increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RXST in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RXST currently overvalued or undervalued?

What is Rxsight Inc (RXST) fair value?

RXST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Rxsight Inc (RXST) is between 8.97 to 21.78 according to relative valuation method.

How does RXST's valuation metrics compare to the industry average?

The average P/S ratio for RXST's competitors is 1.84, providing a benchmark for relative valuation. Rxsight Inc Corp (RXST) exhibits a P/S ratio of 3.41, which is 85.74% above the industry average. Given its robust revenue growth of -18.91%, this premium appears unsustainable.

What is the current P/B ratio for Rxsight Inc (RXST) as of Mar 03 2026?

As of Mar 03 2026, Rxsight Inc (RXST) has a P/B ratio of 1.55. This indicates that the market values RXST at 1.55 times its book value.

What is the current FCF Yield for Rxsight Inc (RXST) as of Mar 03 2026?

As of Mar 03 2026, Rxsight Inc (RXST) has a FCF Yield of -5.20%. This means that for every dollar of Rxsight Inc's market capitalization, the company generates -5.20 cents in free cash flow.

What is the current Forward P/E ratio for Rxsight Inc (RXST) as of Mar 03 2026?

As of Mar 03 2026, Rxsight Inc (RXST) has a Forward P/E ratio of -9.28. This means the market is willing to pay $-9.28 for every dollar of Rxsight Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Rxsight Inc (RXST) as of Mar 03 2026?

As of Mar 03 2026, Rxsight Inc (RXST) has a Forward P/S ratio of 3.41. This means the market is valuing RXST at $3.41 for every dollar of expected revenue over the next 12 months.

RXST Valuation